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Although several tolerance induction protocols have been successfully implemented in 
adult renal transplantation, no tolerance induction approach has, as yet, been defined 
for solid organ transplantations in young infants. Pediatric transplant recipients have a 
pressing demand for the elaboration of tolerance induction regimens. Indeed, since they 
display a longer survival time, they are exposed to a higher level of risks linked to long-term 
immunosuppression (IS) and to chronic rejection. Interestingly, central tolerance induction 
may be of great interest in newborns, because of their immunological immaturity and the 
important role of the thymus at this early stage in life. The present review aims to clarify 
mechanisms and strategies of tolerance induction in these immunologically premature 
recipients. We first introduce the discovery and mechanisms of neonatal tolerance in 
murine experimental models and subsequently analyze tolerance induction in human 
newborn infants. Hematopoietic mixed chimerism in neonates is also discussed based 
on in utero hematopoietic stem cell (HSC) transplant studies. Then, we review the recent 
advances in tolerance induction approaches in adults, including the infusion of HSCs 
associated with less toxic conditioning regimens, regulatory T cells/facilitating cells/mes-
enchymal stem cells transplantation, costimulatory blockade, and thymus manipulation. 
Finally, IS withdrawal in pediatric solid organ transplant is discussed. In conclusion, the 
establishment of transplant tolerance induction in infants is promising and deserves 
further investigations. Future studies could focus on the selection of patients, on less 
toxic conditioning regimens, and on biomarkers for IS minimization or withdrawal.
Keywords: transplantation, tolerance induction, infants, chimerism, stem cells
Abbreviations: ABOi, ABO-incompatible; ALS, antilymphocyte serum; APCs, antigen-presenting cells; BMCs, bone marrow 
cells; BMT, bone marrow transplantation; BN, Brown-Norway; CARs, chimeric antigen receptors; Cas, CRISPR-associated sys-
tems; CNIs, calcineurin inhibitors; CRISPRs, clustered regularly interspaced short palindromic repeats; CsA, cyclosporine A; 
CTL, cytotoxic T lymphocyte; CTLA4, cytotoxic T-lymphocyte-associated protein 4; DCs, dendritic cells; FCs, facilitating 
cells; GvHD, graft versus host disease; HSC, hematopoietic stem cell; HSCT, hematopoietic stem cell transplantation; IS, 
immunosuppression; IUHSCT, in  utero hematopoietic stem cell transplantation; LDLT, living-donor liver transplantation; 
MLR, mixed lymphocyte reaction; MMF, mycophenolate mofetil; MSCs, mesenchymal stem cells; mTECs, medullary thymic 
epithelial cells; NKT, natural killer T; PBMCs, peripheral blood mononuclear cells; pDCs, precursor dendritic cells; PerC, 
peritoneal cavity; PTLD, posttransplantation lymphoproliferative disorder; RBCs, red blood cells; SCID, severe combined 
immunodeficiency; SCT, stem cell transplantation; SOT, solid organ transplantation; TBI, total body irradiation; TCR, T cell 
receptor; Th1 cell, T helper 1 cell; TLI, total lymphoid irradiation; Tregs, regulatory T cells; UCB, umbilical cord blood; VCA, 
vascularized composite allografts.
TABLe 1 | Comparison of immune maturation between mouse 
and human (5).
Functions Mouse Human
Length of gestation 21 days 40 weeks
Lymphohematopoietic 
cells colonize primordial 
thymus
Days 11–12 Week 9
Morphologic division of 
thymus into cortex and 
medulla
Days 13–14 Weeks 11–14
Expression of γδ-TCR 
and αβ-TCR
Days 14–16 Weeks 11–13
Proliferative response 
demonstrable in MLR
Days 16–18 Week 12 (thymus), week 19 
(spleen) (weak until week 23)
Mitogen responsiveness Day 18 (thymus) 
(to some mitogen 
only after birth)
Weeks 13–14 (thymus), 
weeks 16–18 (spleen, 
peripheral blood)
Cytotoxic response 
demonstrable in (CML)
Weak until postnatal 
day 7
Beginning from about weeks 
20–23 (thymus)
TCR, T-cell receptor; MLR, mixed lymphocyte reaction; CML, cell-mediated 
lympholysis.
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iNTRODUCTiON
The neonatal stage is an immune “window phase” susceptible to 
the induction of transplantation tolerance, as described in animal 
models. The phenomenon of fetal immunological tolerance and 
chimerism was noticed in 1945 by Owen (1), who discovered that 
dizygotic twin cattle had two distinct sets of red blood cells (RBCs). 
Indeed, each twin had its own set of RBCs, as well as another set, 
that could only have been derived from the other twin sibling dur-
ing fetal life. In 1949, Burnet introduced the concept of “self ” and 
“non-self ” in immunology (2). He hypothesized that, if cells from a 
genetically distinct individual are implanted and established in the 
embryo, no antibodies should develop against the foreign antigen 
later in life. This hypothesis was proven in 1953 by Medawar and 
colleagues in a murine experimental model, in which allogeneic 
splenocyte injections during the fetal or neonatal stage resulted 
in chimerism and neonatal tolerance without any conditioning 
regimen under certain circumstances (3). Such neonatal toler-
ance induction protocols, though efficient in rodents, cannot be 
transposed into large animals and human neonates who are born 
with an almost entirely functional immune T cell compartment 
(4, 5) (Table 1). Full tolerance of allografts without immunosup-
pressive regimens has rarely been observed, although such cases 
are described in pediatric patients with severe combined immu-
nodeficiency (SCID) that received stem cell transplantation (SCT) 
(6). In adult human recipients, non-myeloablative transplants and 
immunosuppressive regimens followed by the infusion of donor-
derived hematopoietic progenitor cells have been proven to be 
efficient in inducing tolerance to HLA-mismatched renal allografts 
(7). Nevertheless, such non-myeloablative tolerance induction 
protocols have not been used in young pediatric solid organ 
transplant (SOT) recipients. Indeed, a major concern remains with 
respect to the toxicity of non-myeloablative conditioning regimens 
and the effectiveness of present tolerance induction protocols.
At the present time, SOT is more and more frequently per-
formed in infants or even neonates. Approximately 25% of the 
450–550 pediatric heart transplants reported to the Registry of 
the International Society for Heart and Lung Transplantation 
every year concern young infants (<1  year) (8). Compared to 
adult patients, the immune system of these young patients still 
demonstrates immature features and susceptibility to transplant 
tolerance. Clearly, spontaneous engraftment without immu-
nosuppression (IS) has been observed in 25–38% of pediatric 
recipients of liver transplants (9). Besides, ABO-incompatible 
(ABOi) SOT and B cell tolerance can be achieved in young 
infants, due to the relative immaturity of T cell-independent 
antibody responses (5). Under such circumstances, there is a 
strong interest in understanding and implementing tolerance 
induction in pediatric transplantation. The present study reviews 
the current knowledge and recent progress in the field of neonatal 
tolerance and pediatric transplant tolerance, in order to evaluate 
the advantages and challenges associated with the establishment 
of tolerance induction protocols in infants and neonates.
MeCHANiSMS OF NeONATAL 
TOLeRANCe iN MiCe
Although neonatal tolerance was discovered 60  years ago, the 
underlying mechanisms remain to be thoroughly investigated. 
As demonstrated by Medawar and colleagues in their publication 
“‘Actively Acquired Tolerance’ of Foreign Cells” (3), neonatal 
tolerance is based on two main principles, namely, (i) acceptance 
of foreign cells from the original inoculum. Indeed, the engraft-
ment of allogeneic splenocytes or bone marrow cells (BMCs) in 
neonatal recipients does not require any conditioning regimen 
prior to transplantation. (ii) Tolerance to transplanted skin grafts 
from the same donors in adult recipients. The latter should be 
regarded as the maintenance of neonatal tolerance in adulthood. 
It is widely accepted that the tolerance to skin graft in adult life 
relies on central tolerance mechanisms that lead to the clonal 
deletion of donor-reactive thymocytes from the T cell repertoire, 
which arises from the contact and interaction between recipient 
thymocytes and thymic antigen-presenting cells (APCs), derived 
from recipient and donor precursor cells (4). Tolerance induc-
tion through donor-derived stem cell infusions in the case of 
SOT is at least partially based on central tolerance mechanisms. 
Regarding the tolerance of foreign cells in the original inoculum, 
the explanation is more obscure and is still a matter of debate. 
Several hypotheses and models have been proposed, including 
the active and passive models based on the “self/non-self ” notion 
first voiced by Burnet. The T helper 1 (Th1) to Th2 immune devia-
tion in the neonatal stage and the Th17 immune subpopulation 
were also proposed to be important factors facilitating tolerance 
to the original inoculum. Finally, the “danger” concept proposed 
by Matzinger in the immunology field in 1990s (10) may also 
provide some useful clues as to these underlying mechanisms.
The Passive Model
The passive model is based on the clonal selection theory (2). 
It is a thymus-mediated central tolerance model, suggesting that 
neonatal mice present an immature immune system, and are, 
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therefore, incompetent to mount a cytotoxic T lymphocyte (CTL) 
response to reject the donor cells. This would lead to the engraft-
ment of donor cells in the neonatal mouse recipients and to their 
circulation to the thymus to induce tolerance by clonal deletion, 
such as natural self-tolerance. Natural self-tolerance is shaped 
by self-antigens expressed and presented by various types of 
thymic APCs, such as medullary thymic epithelial cells (mTECs) 
and thymic dendritic cells (DCs), present in the medulla (11). 
Depending on the quality and/or quantity of the overall signal 
delivered during the interactions between thymocytes and APCs, 
self-reactive thymocytes undergo either apoptosis (clonal dele-
tion, e.g., negative selection), anergy, or the generation of central 
regulatory T cells (Tregs).
According to the passive model, when semiallogeneic sple-
nocytes are infused intravenously to induce neonatal tolerance, 
donor antigen-specific thymocytes should be quickly depleted 
in the thymus during the process of negative selection. This 
was confirmed experimentally, since within 72 h of injection, 
thymocytes that were able to respond to alloantigens from 
the tolerance-conferring inoculum were no longer detected 
in the mixed lymphocyte reaction (MLR) (12, 13). Moreover, 
recipient T cells with receptors for donor-derived molecules 
could no longer be detected. During the same interval, cells 
bearing donor alloantigens entered into the thymus, spleen, and 
bone marrow of the host, creating a chimerism status in the 
recipients (12, 13).
The importance of chimerism for the induction and mainte-
nance of central tolerance within the thymus was also investigated 
in the passive model. In the study by Hosono et al., recipient mice 
were neonatally tolerized by the intravenous administration of 
either BMCs or peritoneal cavity (PerC) cells from F1 donors. 
BMCs inoculation resulted in 1-year-long deletion of donor-
reactive T cells, which was significantly different to the transient 
loss (1 week after birth) of donor-reactive T cells observed after 
PerC cell inoculation. The tolerant state correlated well with the 
degree and persistence of the intrathymic presence of F1 type 
cells (14). Hosono and colleagues next revealed that inoculated 
cells accumulating in the thymic medulla, but not in the cortex, 
induced tolerance to the MHC-II alloantigens (15). Eto et  al. 
studied the role of chimerism in the establishment of allograft 
tolerance in adult mice conditioned with cyclophosphamide 
and then receiving infusions of allogeneic BM and spleen cells. 
Even when cells were infused at a concentration of 1.2 × 108 (10 
times more than in neonatal mice), neither mixed chimerism 
nor clonal deletion of antigen-specific thymocytes was observed 
in the thymus of 2-week-old mice, whereas both were observed 
at 5 weeks and lasted for more than 10 weeks following the treat-
ment. These results suggest that micro-anatomical barriers that 
limit the entry of foreign cells are less stringent in the neonatal 
rather than in the adult thymus. This difference may explain 
why transplantation tolerance is easier to achieve in murine 
neonates (16).
The Active Model
The active model is based on the immune network theory. It 
suggests that during the neonatal stage, the introduction of 
(CBA × A) F1 antigen into the developing immune system of 
recipient CBA mice may favor a “network interaction.” Hence, 
the F1 antigen recognized by nascent receptors expressed by 
specific peripheral T cells should be especially immunogenic 
to their “anti-idiotype” counterparts (suppressor T cells) and 
should selectively facilitate the expansion of this population 
in order to predominantly suppress the alloreactive response 
(17). The existence of “suppressor T cells” as proposed by the 
active model was then denied by a better understanding of the 
T cell receptor (TCR), but this notion initiated the discovery 
of Treg populations. However, the exact role of Treg in neona-
tal tolerance still remains unknown. Gao et  al. reported that 
neonatal BALB/c mice injected with semiallogeneic CAF1 
(BALB/c × A/J) splenocytes could induce antigen-specific tol-
erance to A/J mice, which lasts into adulthood. These authors 
demonstrated that A/J-specific anergic CD8+ T cells were 
present in neonatal primed mice that developed tolerance but 
not in those that rejected A/J skin grafts. Anergic CD8+ cells 
were regulated by CD4+CD25+ Treg and showed decreased 
proliferation and no CTL activity against A/J targets in  vitro 
(18). Donor-derived Treg may be dispensable in the induction 
of neonatal tolerance (19), but host Treg may play an important 
role in the maintenance of tolerance (20).
Th1 to Th2 immune Deviation
T helper 1 to Th2 immune deviation has been proposed as 
another explanation for neonatal tolerance. It suggests that in 
neonatal mice, the newborn T cells will generate a Th2-biased 
immune response that will protect donor cells from rejection 
(Figure 1). Manifestations of Th2 cytokine bias in neonatal mice 
were demonstrated: (i) in the primary immune response, where 
CD4+ Th1 and CD8+ CTL responses are limited in neonatal mice 
initially inoculated with foreign antigen and (ii) in the secondary 
immune response, where mice immunized during the neonatal 
stage mount Th2-dominated memory responses when re-exposed 
to the same antigen in adulthood (21–23). Moreover, it was dem-
onstrated that blocking of IL-4, the key cytokine involved in the 
development of Th2 cells, prevented the induction of neonatal 
transplantation tolerance in mice inoculated at birth with F1 
splenic cells (24). In conclusion, Th1 to Th2 immune deviation 
at the neonatal stage is considered to have a major impact on the 
immediate acceptance of donor cell inoculum and the following 
donor-specific tolerance induction.
Role of Th17 Cells
Besides Th1 and Th2, the role of Th17 cells in neonatal toler-
ance induction also appears to be important in mice. Th17 cells 
differentiate from naive CD4+ T cells and can produce IL-17, 
IL-21, and IL-22 (25). The cytokine IL-17 is characterized 
by a high inflammatory potential, as it can mobilize, recruit, 
and activate neutrophils that participate in allograft rejection 
(26). It was demonstrated in mice that, concomitantly with the 
development of a Th1-type response, deprivation of IL-4 upon 
F1 splenic cell treatment at birth resulted in the emergence of 
an anti-donor Th17-type response, which could be detected as 
early as 2 weeks of age. These observations suggest that inhibition 
of the neonatal Th2 response may promote Th17 differentiation 
and Th17 alloimmunity, which might prevent the establishment 
FiGURe 1 | Th1 to Th2 deviation and Th17–Treg axis. Following activation by antigen-presenting cells (APCs), naive Th cells can be polarized into different 
effector T cell subsets: T helper 1 (Th1), Th2, Th17, and induced regulatory T (iTreg) cells, depending on the local cytokine environment. Besides iTreg, there is 
another Treg subset, “natural” Treg (nTreg), which develops as a distinct lineage in the thymus. In neonatal mice, newborn T cells generate Th2-biased immune 
response, thus may protect donor cells from rejection. nTreg and iTreg are critical in the mechanism of neonatal tolerance induction. They promote the donor cells 
engraftment and tolerance induction. By contrast, promotion of Th17 immunity can prevent establishment of lymphoid chimerism and neonatal tolerance induction.
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of lymphoid chimerism and neonatal tolerance induction (27). To 
fully address the role of Th17 in neonatal tolerance induction, we 
considered the Th17–Treg axis. Tregs play a critical role in main-
taining self-tolerance and are now considered as an important 
therapeutic target to induce transplant tolerance. However, recent 
studies highlighted that Treg can be subverted by inflammatory 
conditions and converted into Th17 cells (28). Thus, a better 
understanding of the parameters that regulate the Th17–Treg axis 
may also be of interest in the exploration of the therapeutic effects 
of transferred Treg in transplantation (Figure 1).
The “Danger” Model
The “danger” model highlights the role of APCs in neonatal 
tolerance mechanisms. Matzinger and colleagues showed that 
the proportion of APCs in Medawar’s typical donor inoculum 
(3) is the factor controlling tolerance or immune activation (29). 
Medawar’s splenocytes or BM cell suspensions contain a large 
percentage of T and B cells, but very few professional APCs (29), 
which cannot costimulate naive T cells (30–32). Thus, by admin-
istering a pure population of DCs, Matzinger et al. demonstrated 
that neonatal T cells could be activated to produce CTL responses 
(33). They also proposed that the number of cells administered 
was important, and that it was possible to induce tolerance in 
adults, provided that the number of “non-costimulatory cells” in 
the inoculum could be large enough.
When studying the “danger model,” future research may 
focus on the role of the innate immune system in response to 
transplantation. However, a consensus that has been reached is 
that no single theory can explain the function of the immune 
system as a whole. Transplant tolerance is neither a single phe-
nomenon nor is it achieved by a unitary mechanism.
MiXeD CHiMeRiSM AND NeONATAL 
TOLeRANCe: iMPLiCATiON FROM 
IN UTERO HSCT
Since it was discovered by Owen in 1945, hematopoietic mixed 
chimerism has been widely accepted as an important element 
and explanation of tolerance induction. In many experimental 
or clinical transplant studies, induction of mixed chimerism 
via HSCT has become the direct objective and a criterion to 
evaluate tolerance induction. However, the exact relationship 
between mixed chimerism and transplant tolerance has not been 
clarified. In other words, in order to induce tolerance for solid 
organ or composite tissue allograft, the required parameters of 
chimerism, such as duration (transient or durable chimerism), 
level (macro- or micro-chimerism), and location (chimerism 
in peripheral blood or chimerism in lymphoid tissue), are not 
completely understood. Studies on kidney transplantation in 
non-human primates and human patients illustrate that renal 
allograft  tolerance can be induced in recipients even with 
transient chimerism  (7). Nevertheless, studies on composite 
tissue allograft in the swine model emphasize the importance 
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of durable chimerism to maintain the tolerance to skin com-
ponents (34). This might be explained by the involvement of 
different tolerance induction mechanisms in the maintenance of 
tolerance to different allografts. Theoretically, durable chimerism 
may be an indicator of the acceptance of a skin graft. However, 
neonatal transplant tolerance protocols devoid of immunosup-
pressive therapy, such as those applied in rodent species, could 
not be effective in large animals and humans, who are born 
with an almost entirely functional T cell immunity, for which 
a durable allogeneic chimerism may indicate the necessity for 
a more rigorous conditioning protocol. An applicable mixed 
chimerism induction protocol in human neonates must balance 
the potential beneficial outcome and its proper harmful effects. 
To achieve this objective, it is necessary to evaluate the immune 
barrier to allogeneic cell engraftments in newborns. However, 
very few studies have been reported on chimerism and tolerance 
induction in large animals and human neonates. We thus focus 
on chimerism studies conducted after in utero HSCT (IUHSCT) 
in non-defective animals, in order to gain an insight into the 
potential outcome of HSCT in neonates.
MHC-mismatched IUHSCT in fetal mice can give rise to a 
high percentage of mixed chimerism detected at birth, which may 
decrease with age but can still maintain a long-term detectable 
microchimerism (35–37). Carrier et  al. reported that Balb-c 
(H-2d) and C57BL/6 (H-2b) fetal mice, which had received 
intraperitoneal or transplacental transplants of either allogeneic 
or congenic fetal liver cells demonstrated a durable microchimer-
ism in peripheral blood, spleen, and liver beyond 20  weeks of 
age. Allogeneic recipients were also evaluated for donor skin graft 
acceptance at 6 and 12 months of age, and authors concluded that 
a very small proportion of circulating donor cells in the blood or 
the tissues (≤0.1% donor cells) was sufficient for the induction 
and maintenance of tolerance. Moreover, the presence of donor 
cells in the circulating blood was not necessary for long-term 
skin graft acceptance or maintenance of permanent skin graft 
acceptance (35).
Studies on chimerism after xenogeneic or allogeneic IUHSCT 
have been reported in large animal models, including sheep 
(38–43), canine (44), swine (45, 46), and non-human primate 
(47–50) models.
Interestingly, in the study by Mathes et al., 17 outbred Yorkshire 
pig fetuses received at mid-gestation intravascular injections of 
MHC-mismatched, T cell-depleted BMCs harvested from minia-
ture swine (46). Thirteen healthy piglets were born and nine of the 
newborn piglets had detectable levels of peripheral chimerism 
ranging from 0.16 to 1.6% at birth. However, seven piglets lost 
this chimerism at 6–9 weeks of age. Two animals had persistent, 
long-term chimerism with approximately 1% of donor cells in 
peripheral blood. Remarkably, in the nine piglets which were 
chimeric at birth, five received successful donor-matched kidney 
transplantation and three (with or without durable chimerism) 
developed donor-specific tolerance.
In non-human primates, Cowan et al. infused T cell-depleted, 
parental BMCs into early gestation non-defective fetal rhesus 
monkeys (47). Engraftment was detected in eight animals and 
six of them developed a durable chimerism in peripheral blood 
and bone marrow up to 3 years of age. Although the amount of 
donor cells in marrows from long-term engrafted animals was 
<0.1%, in  vitro MLR and cell-mediated lymphocytotoxicity 
studies between the recipient and donor cells indicate that donor-
specific tolerance was induced. In the study by Shields et  al., 
allogeneic BMCs, including a T cell dose ranging from 2.6 × 105 to 
1.1 × 108 cells/kg, were transplanted into female fetal recipients. 
The presence of donor T cells improved chimerism, since seven 
out of eight live-born neonates displayed high levels of chimerism 
(ranging from 0.4 to 12.5%) in cord blood or bone marrow within 
1 month postpartum, although chimerism in the peripheral blood 
did not reach significant levels within the 2 months after birth. 
A lower level of alloreactivity was proven in chimeric animals 
compared to their donors by in vitro MLR. However, infusion of 
donor T cells also increased the risk of GvHD (49). Based on this 
study, Shields et al. investigated the effects of immunosuppressive 
therapy in fetuses for IUHSCT in non-human primates. Macaca 
fetuses received haploidentical, cytokine mobilized HSCT, with a 
combination of the corticosteroid betamethasone and rabbit anti-
human thymocyte globulin. After birth, the level of chimerism in 
the progenitor population was higher in the immunosuppressed 
animals than the control animals (11.3 ± 2.7 versus 5.1 ± 1.5%) 
and remained significantly higher at an age of 14 months onward. 
This study proved the benefit of non-toxic conditioning protocols 
in the context of IUHSCT (50).
Studies on IUHSCT demonstrated the outcome of chimerism 
induction in immunocompetent fetal hosts. In large animal mod-
els, the immune barrier is more efficient at impeding the engraft-
ment of allogeneic HSCs and at generating durable chimerism. 
However, in many studies, the transient microchimerism in 
peripheral blood or lymphoid tissues displayed a positive effect 
in reducing alloreactivity. In clinical studies, full acceptance of 
allogeneic HSCs without IS only occurs in defective fetuses or 
neonates with SCID (6). Thus, it can be concluded that neonatal 
tolerance induction protocols, devoid of conditioning therapy, 
are not reproducible in human neonates, which are born with 
an almost fully competent T cell immunity. However, studies on 
IUHSCT in large animal models suggest that human neonates, as 
immunologically immature individuals, may accept a tolerance 
induction protocol with non-toxic or less toxic conditioning 
regimens.
ADvANTAGeS OF TOLeRANCe 
iNDUCTiON iN HUMAN NeONATeS
In contrast to rodent species, neonatal tolerance induction pro-
tocols were not effective in large animals or human neonates, in 
which/whom the immune system is more competent with regards 
to alloimmunity. But remarkably, compared to adult recipients, 
SOT or hematopoietic stem cell transplantations (HSCTs) in 
human neonates and infants still demonstrate several interest-
ing phenomena, indicating that these young patients may be 
more susceptible to tolerance induction. For example, (i) liver 
transplantations in infants younger than 90  days have similar 
graft acceptance and patient survival compared to those in older 
children and in adults, although these pediatric patients have a 
higher chance of responding to tolerance induction and to the 
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subsequent withdrawal of IS (51–53); (ii) ABOi organ transplan-
tation and B cell tolerance can be achieved in human infants (5); 
and (iii) recipients of umbilical cord blood (UCB) cells experience 
less graft versus host disease (GvHD) than recipients of HSCT 
from an adult donor (54). Thus, an interesting issue for pediatric 
transplant researchers is as follows: as a high-evolved species, how 
much of an advantage do human neonates and young infants still 
possess in transplant tolerance induction? In the previous topics, 
the mechanisms underlying neonatal tolerance were discussed. 
Keeping these mechanisms in mind, the subsequent topics focus 
on the advantages of tolerance induction in human neonates.
Advantage Corresponding to the 
Mechanism of Passive Model
In neonatal tolerance, the passive model emphasizes the defective 
alloimmunity of neonatal mice, but in large animals and human 
neonates, T cell alloimmunity is highly competent. Although 
human newborns have a large percentage of CD45RA+ naive 
T cells but few memory T cells, as well as a higher percentage 
of CD4+ helper T cells and lower percentage of CD8+ cytotoxic 
T cells (55–59), these T cells showed normal in vivo responses 
to allogeneic stimulators, through both T cell proliferation and 
cytokine production. In one of our experimental studies, newborn 
pigs could effectively mount acute rejection to composite tissue 
allograft (containing bone, muscle, and skin components) on days 
4–8 after transplantation (60). However, fewer memory T cells 
in newborn recipients may be beneficial for transplantation (61), 
since T cell memory is a great obstacle to tolerance induction.
In contrast, B cell immunity is less developed and more plastic 
in human newborns. Neonates and very young infants are able to 
produce IgM, IgG, and IgA antibodies under antigen exposure. 
However, the neonatal humoral response often has a delayed 
onset, reaches lower peak levels, and has a shorter duration (58, 
62, 63). The neonatal B cell pool contains a higher proportion 
of B1 cells, which produce natural antibodies (mainly IgM) with 
low-binding affinity and are not able to differentiate into memory 
B cells (64). The very young infants have a low level of produc-
tion of natural antibodies (isohemagglutinins) against blood 
group antigens that are not completely expressed on their own 
tissues, providing them with the ability to tolerate ABOi organ 
transplantation (65–68).
The central tolerance mechanism is involved in the passive 
model, highlighting the importance of the thymus. The thymus is 
a relatively large organ in the newborn infant. In contrast to adult 
recipients, in whom the thymus has undergone a gradual involu-
tion, the existence of a potent thymus enables the very young 
recipients to be a special immune host during tolerance induction 
procedures. The thymus plays a major role in the development 
of self-tolerance. Thymocytes undergo both positive and nega-
tive selection, resulting in the development of a T cell repertoire 
with a broad range of reactivity to foreign antigens, but without 
reactivity to self-antigens. The thymus was proven to be critical 
in the induction of donor-specific tolerance (69). Proper donor 
antigen presentation in the thymus after HSCT or SOT has been 
shown to induce tolerance to allografts. Several studies proved 
that thymectomy could result in acute cellular rejection or failure 
of tolerance induction (70, 71).
Role of Natural Treg
It has been proven that natural Treg (nTreg) may be able to 
facilitate allograft tolerance induction in early life stages (18, 20). 
Compared to induced Treg in adults, nTreg in neonates display 
higher levels of expression of immature markers, such as CD45RA 
and TCR recombination excision circles (TREC), cytotoxic 
T-lymphocyte antigen 4 (CTLA4), and forkhead box P3 (Foxp3). 
Thus, nTreg is regarded as a functionally mature population with 
a naive phenotype. In humans, researchers have proven that 
cord blood of preterm newborns contained a high proportion 
of CD4+CD25+ nTreg, which declined with gestational age (72). 
This unique population of regulatory cells may promote tolerance 
induction in neonates and very young infants. The thymus may 
also have significance in such mechanisms, since it is the source 
of nTreg cells (69).
Th1 to Th2 Deviation in Human Neonates
Although widely accepted as immunocompetent, human neona-
tal T cell immunity is biased toward a Th2 response. Disruption 
of Th1 cell responses have been observed following certain infec-
tions and immunizations (73–77). But compared to mice, the Th2 
bias is not as pronounced in human neonates, since lower levels of 
all cytokines can be detected (78). Recently, several studies have 
shown that neonatal B cells demonstrated an immunoregulatory 
function (30, 79, 80).
Advantage Corresponding to the 
Mechanism of “Danger” Model
Antigen-presenting cells mainly include DCs, monocytes, and 
macrophages. The defective APC functions have been reviewed 
by Velilla et al. (81). Converse to neonatal T cells, neonatal APCs 
are deficient in the production of cytokines, such as TNF-α, IL-1, 
IL-6, or IL-12, in response to bacterial lipopolysaccharide (LPS) or 
CD40-signaling (75, 82–85). APCs from human cord blood also 
appear to be immature as they exhibit low or no basal expression 
of costimulatory molecules, including CD40, CD80, or CD86 (86, 
87). The intrinsic deficiencies of the APC function in neonates 
subsequently results in the defective interaction between APCs 
and T cells, which could lead to secondary defects of adaptive 
T cell responses. Moreover, neonatal nTreg can downmodulate 
the function of both APCs and T cells through direct and indirect 
mechanisms (81).
TOLeRANCe iNDUCTiON APPROACHeS 
iN iMMUNOLOGiCALLY MATURe 
ReCiPieNTS
To the best of our knowledge, until now there is no study of 
tolerance induction through donor cells infusion conducted in 
pediatric patients. All of such clinical trials are performed in adult 
patients. Thus, we cited these clinical trials in order to discover 
the potential strategies for tolerance induction in infants. These 
clinical trials can be divided in three types: (1) tolerance induction 
through HSCT under non-myeloablative and lymphodepletive 
conditioning regimens; (2) transplantations of Treg, facilitating 
cells (FCs), or mesenchymal stem cells (MSCs); and (3) T cell 
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costimulatory blockade, respectively, their principles correspond 
to passive model, active model, and danger model.
HSCT via Non-Myeloablative and 
Lymphodepletive Conditioning Regimens
According to the passive model, neonatal tolerance can be 
induced in neonatal mice, owing to the defective immune system 
of the recipient. For immunologically mature recipients, toler-
ance induction could be achieved by mimicking such a defective 
immune system, by partially destroying the immune system of 
the recipients by a “conditioning” regimen.
Non-Myeloablative Conditioning Regimens  
in Animal Models
Following the discovery of tolerance in neonatal mice by 
Medawar’s team, subsequent studies revealed that tolerance can 
also be induced in adult mice. In 1955, Main and Prehn (88) 
demonstrated that under myeloablative conditioning, adult 
mice that received allogeneic BMC infusions were rescued from 
ablation and were also tolerant to donor skin grafts. Success of 
tolerance induction was also extended from the rodent model to 
large animal models. In 1972, with a canine model, Rapaport et al. 
confirmed that induction of unresponsiveness to canine renal 
allografts could be achieved by total body irradiation (TBI) and 
bone marrow transplantation (BMT) (89). Thereafter, induction 
of tolerance to organ transplants by hematopoietic chimerism was 
confirmed in all of the large animal models tested (90). Although 
myeloablative conditioning was acceptable for the use of HSCT 
in hematologic malignancy, the relevant risk of complications was 
unacceptable when applied to non-malignant situations of solid 
organs and composite tissue allotransplantation.
Therefore, protocols for performing HSCT for tolerance 
induction involving non-myeloablative conditioning became the 
focus of subsequent studies. Ildstad et al. first reconstituted the 
lethally irradiated adult mice with T cell-depleted bone marrow 
containing both recipient and donor components. As former 
study, this therapy led to long-term survival of the reconstituted 
animals and specific prolongation of subsequent skin grafts of 
donor type. Animals reconstituted in this fashion were fully 
reactive to third-party allografts and did not appear to manifest 
signs of GvHD (91). Sharabi and Sachs evaluated the outcome 
of tolerance induction of unmanipulated fully MHC-disparate 
BMT under non-lethal conditioning regimens. The results 
demonstrated that stable mixed chimerism with donor-specific 
tolerance can be induced in skin graft across an MHC barrier 
after a non-lethal preparative regimen, without clinical GvHD 
and without the risk of aplasia (92). Colson et al. also reported 
that durable multilineage mixed allogeneic chimerism and 
donor-specific transplantation tolerance for skin, and primarily, 
cardiac vascularized allografts can be achieved across multiple 
histocompatibility barriers using a non-myeloablative radiation-
based regimen (93). Similarly, non-myeloablative radiation-
based regimens were subsequently extended successfully to the 
induction of tolerance to renal transplants in fully mismatched 
cynomolgus monkeys (94, 95).
In the swine model, mixed chimerism across both minor and 
major histocompatibility barriers can be established using high 
doses of peripheral blood stem cells (200 × 108 cells/kg) in the 
absence of whole body irradiation (96). Interestingly, a major 
finding of these studies was that animals with 1% peripheral blood 
donor chimerism showed just as much tolerance as those with 
100% donor chimerism, suggesting that complete replacement of 
the recipient hematopoietic system with that of the donor is not a 
prerequisite to tolerance induction. It was also hypothesized that, 
although chimerism was required to induce tolerance, it was not 
necessary for its maintenance and that immune regulation would 
be able to maintain the tolerant state after the loss of chimerism. 
Donor antigen from the kidney allograft was believed to directly 
contribute to the regulatory mechanism (97).
Non-Myeloablative Conditioning Regimens in  
Clinical Kidney Transplantation
Tolerance induction protocols involving non-myeloablative 
conditioning subsequently evolved into clinical trials in the case 
of kidney transplantation (Table 2) after the success obtained in 
animal experiments. The following paragraphs focus on clinical 
protocols that have been performed in HLA-identical and HLA-
mismatch renal transplants.
In the HLA-identical renal transplantation study by Scandling 
et al. in Stanford University (98, 99), 16 patients conditioned with 
total lymphoid irradiation (TLI) and ATG were given kidney 
transplants and an injection of 10 × 106/kg CD34+ hematopoietic 
progenitor cells and 1 × 106/kg CD3+ T cells from HLA-matched 
donors. Fifteen patients developed multilineage chimerism 
without GvHD and eight individuals with chimerism for at 
least 6 months were withdrawn from anti-rejection medications 
for 1–3 years (mean, 28 months) without subsequent rejection 
episodes. Blood cells from all patients showed high ratios of 
CD4+CD25+ Treg and natural killer T (NKT) cells versus conven-
tional naive CD4+ T cells at an early stage, and those drugs showed 
specific unresponsiveness to donor alloantigens. A clinical trial 
of HLA-mismatched renal transplantation in Massachusetts 
General Hospital began in 2002 (7, 100). Ten patients received 
combined bone marrow and kidney transplants from HLA 
single-haplotype mismatched living-related donors, with the 
use of a non-myeloablative preparative regimen similar to HLA-
matched renal transplantations (Table 2). Transient chimerism 
and reversible capillary leak syndrome developed in all recipients. 
Overall, the outcome from HLA-mismatched kidney transplants 
is not as satisfactory as those from HLA-matched transplants: 
3/10 patients experienced graft loss; 3/10 patients in the first 
cohort developed chronic humoral rejection and mycophenolate 
mofetil (MMF) was re-administrated in 2 of them; 3/10 patients 
in the second cohort remained stable, but a long-term monitoring 
was necessary; and 1/10 patient remained healthy and without 
rejection for over 10 years (90).
Lymphodepletive Conditioning Regimens
As discussed above, non-myeloablative protocols for tolerance 
induction were introduced in experimental BMT studies. However, 
conventionally, conditioning of the recipient still required TBI, 
thymic irradiation, or cytotoxic drugs, such as cyclophosphamide. 
The potential toxicity associated with cytoreductive conditioning 
is a major reason preventing these protocols from being routinely 
TABLe 2 | Comparison of different non-myeloablative conditioning protocols for tolerance induction in renal transplantation.
Therapies MGH protocol (7, 100) Stanford protocol (98, 99) NMH protocol (90, 103)
Renal transplantation Related, HLA mismatched (day 0) Related, HLA identical (day 0) Related or unrelated, HLA mismatched (day 0)
Donor-derived cells 
infusion
BMCs (day 0) G-CSF mobilized CD34 + HPCs and 
CD3+ T cells (day 0)
G-CSF mobilized, FC-based HSCs, αβ-T cells 
(day 1)
Lymphodepletion by 
mono- or poly-clonal 
antibodies
Rituximab (375 mg/m2, days −7 and −2),  
anti-CD2 mAb (0.6 mg/kg, days −1, 0, and 1)
ATG (1.5 mg/kg/day, days 0–5) None
Cytoreductive  
medication
Cy (50 mg/kg/day, days −5 and −4) None Cy (50 mg/kg/day, days −3 and +3), Flu 
(30 mg/kg/day, days −4, −3, and −2)
Irradiation Thymic irradiation (700 cGy, day −1) TLI (80 or 120 cGy/day, days 1–11) TBI (200 cGy, day −1)
Maintenance 
immunosuppression
Prednisone (days 0–10), CsA Prednisone (days 0–10), CsA, 
and MMF
Tacrolimus and MMF
MGH, Massachusetts General Hospital; NMH, Northwestern Memorial Hospital; HLA, human leukocyte antigens; BMC, bone marrow cell; G-CSF, granulocyte colony stimulating 
factor; HPC, hematopoietic progenitor cell; HSC, hematopoietic stem cell; ATG, rabbit anti-thymocyte globulin; Cy, cyclophosphamide; Flu, fludarabine; TLI, total lymphoid 
irradiation; TBI, total body irradiation; CsA, cyclosporine A; MMF, mycophenolate mofetil.
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implemented in the clinical context. To increase the potential 
clinical acceptability of such regimens, it would be desirable to 
improve the success rate of such protocols and to achieve chimer-
ism and tolerance avoiding cytoreductive conditioning.
Conception of lymphodepletion-based conditioning regimen 
was developed under such circumstances. In 1970, Gozzo and 
Monaco reported that allogeneic, homozygous donor BMC infu-
sion under lymphocyte-depleting condition with antilymphocyte 
serum (ALS) significantly prolonged graft survival time in mice 
(101). Later, Monaco et al. introduced similar conditioning and 
BMT protocols to human kidney transplantation (102). One recipi-
ent was given ALS (first 14 days after renal transplant) and 11 × 109 
donor BMCs (at day 25 post-operation) along with conventional 
doses of prednisone and azathioprin. The conventional immuno-
suppressive agents were tapered, and renal function was normal 
8 months following transplantation. Histological examination of 
the renal allograft showed only minimal evidence of rejection.
Nowadays, this lymphodepletion-based conditioning 
regimen has been successfully implemented in HLA-identical 
renal transplantation in the clinical trial of the Northwestern 
University, which was initiated in 2008 (90, 103). In this study, 
20 cases of HLA-identical sibling donor–recipient pair renal 
transplants were performed using this conditioning regimen. 
Lymphodepletion was induced by administering alemtuzumab, 
and four infusions of donor CD34-selected HSCs were then 
performed postoperatively during the first 9 months following 
renal transplantation. Conventional IS was tapered and con-
verted to sirolimus monotherapy. Transient microchimerism 
was the only phenomenon present, and it had disappeared at the 
1-year follow-up examination. IS is generally withdrawn within 
24  months in subjects with stable renal function and normal 
protocol biopsies. At the time of this publication, patients in the 
study ranged from 2 to 52  months posttransplant and 50% of 
these recipients have taken off immunosuppressive agents for 
over 1 year. None of the 20 subjects displayed any deterioration 
of their renal function, such as that occurring in the early post-
transplant period. Increased numbers of CD4+CD25highFoxP3+ 
Treg were observed in the peripheral blood of these patients 
during lymphoid reconstitution, suggesting the induction of 
an immunoregulatory state. This tolerance induction protocol 
excludes the need for permanent chimerism but focus on a 
prolonged immunoregulatory environment, which could be 
provided by donor HSC infusions in the setting of HLA-identical 
renal transplantation.
Transplantations of Treg, FCs, or MSCs for 
Tolerance induction
The active model of neonatal tolerance that focused on the func-
tion of “suppressor cells” has been proven to be wrong. However, 
the concept of “suppressor cells” continues to develop and has 
resulted in the discovery of Treg. If we extend the notion of active 
model, which emphasizes the tolerogenic cells in the inoculum, 
we can include several cell therapies, namely, transplantation of 
Tregs, FCs, and MSCs. These cell therapies have been introduced 
into clinical trials for the purpose of tolerance induction in BMT, 
SOT, or autoimmune diseases.
Transplantation of Treg
Regulatory T cells have been shown to be efficient in controlling 
auto- and alloimmunity in preclinical studies and have recently 
been included in clinical studies. To date, approximately four 
clinical trials have been reported using Treg therapy in humans, 
three in GvHD (104–106) and one in type 1 diabetes (107). 
Clinical trials involving the infusion of Treg for promoting toler-
ance induction to solid organ allograft have not been reported 
but have been registered in www.clinicaltrials.org, including liver 
transplantation (NCT 01624077) and kidney transplantation 
(NCT 01446484).
A clinical trial of ex vivo expanded Treg was initially reported 
by Trzonkowski et al. in 2009, for the treatment of GvHD (104). In 
this study, two patients who suffered from either acute or chronic 
GvHD were enrolled. CD4+CD25+CD127− Tregs were sorted 
from buffy coats taken from two family donors, expanded ex vivo, 
and transferred to respective recipients. This therapy significantly 
alleviated the symptoms and reduced pharmacologic IS in the 
case of chronic GvHD, while in the case of grade IV acute GvHD 
it only transiently improved the condition. Brunstein et al. first 
evaluated the safety profile and therapeutic effects of UCB Treg in 
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23 patients (105). CD4+CD25+FoxP3+ Tregs from cryopreserved 
UCB were ex vivo expanded and then infused into recipients after 
double UCB transplantation. Following Treg infusion, there was 
a reduced incidence of grade II–IV acute GvHD without any del-
eterious effects on the risk of infection, relapse, or early mortality. 
In the trials of Di Ianni et al., the impact of donor Treg was studied 
in the context of HLA-haploidentical SCT (106). Twenty-eight 
patients received infusion of immunoselected CD4+CD25+ Treg, 
followed by transplantation of immunoselected CD34+ cells and 
mature CD4+CD25− T cells from the same donor. Results showed 
that (i) 26/28 patients were engrafted, (ii) acute GvHD developed 
in only 2/26, and (iii) no patient developed chronic GvHD. In 
addition, in the trials of Marek-Trzonkowska et al., autologous 
CD3+CD4+CD25highCD127− Tregs were sorted from peripheral 
blood and used to treat type 1 diabetes in children, resulting in a 
highly satisfactory outcome (107).
Interestingly, recent researches showed that chimeric antigen 
receptors (CARs) may be an effective way to produce a sufficient 
amount of antigen-specific Tregs for clinical applications. CARs 
are created by combining antibody variable domains with TCR-
signaling domains (108, 109). Furthermore, with their high level 
of flexibility but specific targeting, clustered regularly interspaced 
short palindromic repeats (CRISPRs) and CRISPR-associated 
systems (Cas), which have become powerful tools for genome 
editing, might play an important role in the production of engi-
neered antigen-specific Tregs (110).
A major question for Treg therapy is that Tregs can be con-
verted into Th17 cells under inflammatory conditions. Therefore, 
it is, important to study whether the adoptively transferred Treg 
lines can be diverted into a Th17 response and fulfill their role 
in the response to organ transplantation. The development of 
therapeutic strategies focusing on the shift of the Th17–Treg 
axis toward the stabilization of the Treg population would be an 
interesting future prospective.
Co-Infusion of FCs in HSCT
CD8+/TCR− FCs have been shown, in experimental studies, 
to potently enhance engraftment of allogeneic HSCs without 
causing GvHD (111, 112). The predominant subpopulation of 
FCs resembles plasmacytoid precursor dendritic cells (pDCs) 
(113). Bone marrow-derived plasmacytoid dendritic cells induce 
naive T cells to differentiate to become antigen-specific Treg, 
thus facilitating the induction of allogeneic HSCs engraftment 
(114). Co-infusion of FCs may circumvent major issues raised by 
tolerance induction of solid organ or composite tissue allograft 
through HSCT, by improving chimerism, and concomitantly by 
using less toxic conditioning regimens. Recently, clinical trials 
based on FC infusions with HSCT have been conducted, and the 
outcome of this trial proves this may be a promising therapy for 
tolerance induction in pediatric recipients (115, 116).
A novel approach was reported by Leventhal et al. who bio-
engineered human marrow to remove GvHD-inducing immune 
cells and to preserve FC, HSC, and progenitor cells. This approach 
was followed by the fist clinical trial based on myeloablatively 
conditioned, mismatched BMT in 54 recipients with hemato-
logical malignancies. Results confirmed the function of FCs in 
facilitating engraftment and avoiding the occurrence of GvHD 
(90). The success of this first resulted in the implementation of 
subsequent clinical trials using FCs for tolerance induction in 
kidney transplant recipients (116). Fifteen HLA-mismatched, 
-related, and -unrelated subjects were enrolled. Conditioning 
consisted of three doses of fludarabine on days −4, −3, and −2; 
two doses of cyclophosphamide on days −3 and +3; and 200 cGy 
TBI on day −1. Administration of tacrolimus and MMF was 
initiated on day −3 and was continued in order to maintain IS 
after the transplant procedure. Kidney transplantation was per-
formed (day 0) without antibody induction or oral corticosteroid 
therapy. The bioengineered HSC product, enriched for FCs, was 
infused intravenously on the day after kidney transplantation. 
The conditioning was well tolerated with outpatient management 
after day 2. In follow-up examinations, high levels of peripheral 
blood chimerism (6–100%) were observed in 14/15 patients. All 
subjects demonstrated donor-specific hyporesponsiveness and 
were weaned from full-dose IS. Complete withdrawal of IS was 
successfully accomplished 1 year after transplantation in all of the 
subjects with durable chimerism. There has been no occurrence 
of GvHD or engraftment syndrome. These results suggest that 
manipulation of a mobilized stem cell graft and non-myeloablative 
conditioning represent a safe, practical, and reproducible means 
of inducing durable chimerism and donor-specific tolerance in 
SOT recipients.
Transplantation of MSCs
Findings obtained from experimental studies of SOT or HSCT 
proved that MSCs facilitate the induction of transplant tolerance 
(117). Clinical studies of MSCs transplantation in SOT or HSCT 
recipients are currently underway, and preliminary results from 
the clinical trials have been reported (118).
In the clinical trial of Perico et  al., autologous MSC infu-
sion was conducted in two kidney transplant recipients (119). 
Patients were given T cell-depleting induction therapy, and IS 
was maintained using cyclosporine A (CsA) and MMF. On day 7 
posttransplant, MSCs were administered intravenously. Findings 
from this study show that MSC infusion in kidney transplant 
recipients is feasible; it allows enlargement of Treg in the periph-
eral blood and controls the function of memory CD8+ T cells. 
However, serum creatinine levels increased 7–14 days after cell 
infusion in both MSC-treated patients. A graft biopsy in one 
patient excluded acute graft rejection but showed a granulocyte-
mediated focal inflammatory infiltrate. Of note, an experimental 
study conducted on murine kidney transplant showed that a 
single administration of MSC before (day 1), but not after renal 
transplantation, avoided the acute deterioration of graft function 
while maintaining the immunomodulatory effect associated 
with MSC treatment (120). In subsequent trials, two kidney 
transplant recipients were given pretransplant (day 1) infusion of 
BM-derived autologous MSC before T cell-depleting induction 
therapy (121). In the first patient, MSC treatment was uneventful 
and graft function was normal during the 1-year follow-up. In 
the second patient, however, acute cellular rejection occurred 
2 weeks after posttransplant. These studies indicate that autolo-
gous MSC may have a low capacity to control the host immune 
response at an early-stage posttransplantation in the context of a 
high alloreactive environment.
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A clinical trial conducted by Tan et al. showed that during 
the 1-year follow-up, MSC-treated patients had a significantly 
lower risk of opportunistic infections than those not receiving 
the MSCs infusion (122). However, in the study by Reinders 
et al., six renal transplant recipients who were given two doses 
of autologous BM-MSCs showed signs of subclinical rejection 
and/or an increase in interstitial fibrosis/tubular atrophy in renal 
biopsies, 4 weeks or 6 months posttransplantation. Besides, five 
out of six patients displayed a donor-specific downregulation 
in the ex vivo peripheral blood mononuclear cell (PBMC) pro-
liferation assay, whereas three patients developed an opportun-
istic viral infection (123). Authors concluded that MSC could 
induce over-IS. These studies suggest a careful monitoring 
of the side effects of MSC therapies, especially in chronically 
immunosuppressed transplant recipients, who are already at 
an increased risk of contracting infections and malignancies 
(118, 124).
T Cell Costimulatory Blockade 
in Organ Transplantation
According to the “danger model” theory, T cell costimulatory sig-
nals play an important role in neonatal tolerance induction (33). 
Theoretically, donor BMT combined with the administration of 
T cell costimulatory blockade agents could thus, at least partially, 
mimic the conditions in neonatal mice, facilitating tolerance 
induction in the immunologically mature recipients. Currently, 
tolerance induction protocols with non-lymphodepletive, 
non-toxic conditioning regimens have been developed, mainly 
containing costimulation blockade agents and routine immuno-
suppressive drugs.
In the mouse model, Blaha et al. introduced a tolerance induc-
tion protocol, including BMC infusions, anti-CD40L monoclonal 
antibody (blockade of CD40: CD154 costimulatory pathway), 
and CTL-associated protein 4 (CTLA4)-Ig (blockade of CD28: B7 
costimulatory pathway) administration in addition to short-term 
IS (rapamycin, methylprednisolone, and MMF for 4 weeks after 
BMT). This protocol led to long-term multilineage chimerism in 
28/30 recipients and to the significant prolongation of skin graft 
survival (125).
In a large animal model, Wachtman et  al. confirmed the 
beneficial effect of CTLA4-Ig for inducing tolerance to vascular-
ized composite allografts (VCA) in swines (126). In this study, 
miniature swines received MHC-mismatched hind limb VCA 
and were administered with CTLA4-Ig on days 0, 2, 4, and 6, 
in addition to a 30-day treatment course of tacrolimus, though 
no cytoreductive conditioning regimen or extra donor BMCs 
infusions were given. The recipients demonstrated indefinite pro-
longed muscle survival, and the skin component also displayed 
remarkably prolonged survival. Although further study on the 
underlying mechanisms is required, a possible explanation might 
be that the bone marrow component in the hind limb allograft 
might have benefited from the costimulatory blockade protocol 
and, therefore, microchimerism was developed to regulate the 
recipient alloimmune response.
In non-human primates, Lo et al. developed a belatacept-based 
regimen without HSCT in rhesus monkeys. The rhesus monkeys 
studied, received MHC-mismatched renal allotransplants with IS 
containing belatacept, mammalian target of rapamycin inhibitor, 
and sirolimus. This therapy successfully prevented allorejection in 
all animals. However, tolerance was not induced, since allografts 
were rejected after withdrawal of IS, indicating the important 
role of HSC infusions (127). In a MHC-defined rhesus macaque 
BMT model, Page et  al. evaluated a non-lymphodepletive 
conditioning protocol combined with the administration of the 
CD40 monoclonal antibody, CTLA4-Ig, and sirolimus to produce 
mixed chimerism by HSCT. Results showed that prolonged 
HSC engraftment required the presence of all three agents dur-
ing maintenance therapy and resulted in graft acceptance for 
the duration of immunosuppressive treatment. In this study, 
although complete withdrawal of IS was not achieved, notably, 
this protocol excluded the use of calcineurin inhibitors (CNIs) 
and steroids (128).
Recently, CD28 blockade has been successfully transposed 
to the clinical setting with the commercialization of belatacept. 
Transposition of blockade of the CD154:CD40 pathway has been 
less successful, due, in large part, to thromboembolic complica-
tions associated with anti-CD154 antibodies. Transposition of 
CD40 blockade has also been slow, partly due to the fact that 
the synergy between CD40 and CD28 blockade had not yet been 
demonstrated in either primate models or humans. So far, toler-
ance induction protocols based on costimulatory blockade agents 
have not yet reached the stage of clinical trials. Remarkably, 
however, in maintenance therapy, conversion from CNI-based IS 
to belatacept has been performed in renal transplant recipients, 
which may significantly reduce the side effects of chronic CNI 
therapies, such as hypertension, new-onset diabetes, tremor, and 
thrombotic microangiopathy, and can thus improve long-term 
allograft function and patient health (129).
eXPeRieNCe AND STRATeGY OF 
PeDiATRiC TOLeRANCe iNDUCTiON
Current improvements in immunosuppressive and antiviral 
regimens, advances in surgical or organ preservation techniques, 
and progress in donor organ allocation have significantly pro-
longed the survival times of both the patient and the allografts 
(130). Thus, children and adolescent transplant recipients are 
confronted with increased risks of opportunistic infections and 
tumors, aggravated long-term side effects and toxic effects of 
immunosuppressive medications, including impact on growth. 
They are also challenged by graft vasculopathy and chronic 
rejection. Besides, adolescents have the worst patient and graft 
survival, mainly as a result of non-adherence. Taken together, 
young pediatric recipients have a greater demand for successful 
transplant tolerance protocols (131).
To date, clinical trials of tolerance induction through HSCT 
are mostly conducted in adult patients in Massachusetts General 
Hospital (7, 100), Stanford University (98, 99, 132), and Northwestern 
Memorial Hospital (116), as previously mentioned. However, a safe 
and effective tolerance induction protocol in pediatric patients has 
not been defined. In pediatric SOT, only a few studies regarding 
tolerance induction or withdrawal of IS have been reported, most 
of which are concerning to liver transplantation, because of the 
immune-privileged status of the liver (131, 133–136).
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In pediatric living donor liver transplantation (LDLT), the suc-
cess rate of IS withdrawal (operational tolerance) is about 20%, 
which is thus higher than adult recipients (131). Although no 
tolerance induction regimen was administered, HSCs within the 
transplanted liver could have contributed to the development of 
chimerism and to this high “tolerance rate.” Typically, Alexander 
et al. reported that a 9-year-old girl with acute fulminant hepatitis 
after a non-specific viral illness developed complete hematopoi-
etic chimerism and tolerance after receiving a liver allograft from 
a deceased male donor, with no evidence of GvHD (134). Two 
cases of pediatric liver transplant combined with HSC infu-
sions have been reported and both of them achieved functional 
tolerance and showed an excellent clinical outcome (133, 135). 
In the report of Matthes-Martin et al., a 4-month-old girl with 
familial hemophagocytic lymphohistiocytosis received HLA-
mismatched, maternal LDLT. After transplantation, the presence 
of maternal cells in the peripheral blood was observed following 
microchimerism analysis. The patient then received SCT from 
the same donor. Conditioning regimen consisted of busulfan, 
cyclophosphamide, thiothepa, and ATG. Four months after SCT, 
the patient was disease-free, with complete donor chimerism 
in bone marrow and stable hepatic graft function without any 
immunosuppressive therapy (135).
When other SOTs are considered, clinical operational toler-
ance is significantly less common. After the first successful 
pediatric renal transplantation was performed in 1954, only 
sporadic cases of operational tolerance to renal allograft have 
been documented, as review by Orlando et al. in 2008 (136). In a 
report by Roussey-Kesler et al., two recipients received deceased 
donor kidney transplant at pediatric age. In one patient, IS was 
interrupted because of non-compliance and had a stable graft 
function 16 years after withdrawal. The other patient developed 
posttransplantation lymphoproliferative disorder (PTLD) 8 years 
after transplant, relative to Epstein–Barr virus infection. At the 
time of the report, he was 8 years after PTLD treatment and he had 
stable renal function (137). However, studies of IS minimization 
have achieved great success in renal transplant recipients, includ-
ing the pediatric population (138). Steroid-withdrawal (139) or 
steroid-free IS (140) protocol, CNI-free IS protocol (completed 
clinical trial NCT00023231 on www.clinicaltrials.gov) have been 
studied for pediatric renal transplantation.
Besides, clinical operational tolerance has never been reported 
in intestinal, islet, or whole organ pancreas transplantation, 
whereas two exceptional cases of IS withdrawal have been 
described after lung (141) and heart transplantation (142).
THYMiC MANiPULATiONS AS AN 
APPROACH FOR TOLeRANCe 
iNDUCTiON iN iNFANTS
The thymus is a highly developed lymphoid organ in the 
neonatal stage, making infants the ideal recipients for organ 
transplantation. The existence of a functional thymus may also 
improve the outcome of central tolerance induction by intra-
thymic depletion of alloreative T cells, as it has frequently been 
proven that the thymus plays an indispensable role in preclinical 
studies of donor-specific tolerance induction. According to 
previous experimental and clinical studies aimed at exploring 
central tolerance in humans, two main manipulations involving 
in the thymus have been reported, namely, donor thymic tissue 
transplantation and intrathymic injection of donor antigen.
Donor Thymic Tissue Transplantation
Thymic tissue transplantation has been studied since the 1960s, 
when prior to the success of the BMT, many attempts were made 
in order to reconstitute the immunological capacity in infants 
with lymphopenic immunological deficiency by implanting fetal 
or infantile tissues and/or adult blood or bone marrow (143). In 
1969, De Koning reported a case of transplantation of fetal thymus 
and bone marrow cells in a 5-month-old infant with lymphopenic 
immunological deficiency, and the clinical outcome was excel-
lent (144). However, the thymus transplantation procedures were 
performed in the scope of BMT and not aimed at donor-specific 
tolerance induction.
Hence, early thymus transplantations were conducted in mice. 
So far, inducing donor-specific tolerance by thymic tissue trans-
plantation across allogeneic and xenogeneic barriers has been 
achieved in immunocompetent mice after thymectomy, followed 
by lethal whole body irradiation (145, 146), TLI (147), or T cell 
and NK cell depletion with monoclonal antibodies (148). Non-
vascularized thymic tissue allograft was subsequently extended to 
large animal models (149–151). Typically, Haller et al. reported 
thymic transplantation across an MHC class I barrier in min-
iature swine and concluded that thymic transplantation could 
serve as part of a regimen to induce donor-specific tolerance to 
xenogeneic organ grafts (149). In the context of heart transplanta-
tion, Johnston et al. developed a novel technique, in which the 
donor heart and en-bloc thymus grafts were prepared allowing 
the preservation of the entire arterial supply and venous drainage 
of the right thymic lobe (152). This technique thus enabled donor 
thymus transplantations that may prove to be useful in human 
heart transplantation.
Donor thymus co-transplantation with solid organ for toler-
ance induction, although shown to be effective in small and large 
animal models, has so far never been performed in the context of 
clinical organ transplantation. Currently, thymus transplantation 
only serves as a treatment for pediatric patients with profound 
primary immune deficiency due to primary athymia and the 
resulting lack of functional T cells, such as DiGeorge syndrome. 
The main complication that should be addressed is GvHD (153).
intrathymic injection of Donor Antigen
An earlier study focusing on central tolerance induction by intra-
thymic injection of donor antigen was reported by Remuzzi et al. 
(154). In this study, isolated glomeruli from Brown-Norway (BN) 
rat kidney were inoculated into the thymus of MHC-mismatched 
Lewis rats pretreated with CsA for 2 days and administered subcu-
taneous dexamethasone at the time of inoculation. Ten days later, 
the kidneys of the BN rats were transplanted into the intrathymic 
injected Lewis rats. Donor-specific unresponsiveness allowed the 
renal allograft to survive indefinitely without further IS. Many other 
studies in rodent models have also shown that intrathymic injec-
tion of donor antigen in various forms, such as donor spleen cells, 
12
Pan et al. Transplant Tolerance Induction in Newborn Infants
Frontiers in Immunology | www.frontiersin.org April 2016 | Volume 7 | Article 116
ReFeReNCeS
1. Owen RD. Immunogenetic consequences of vascular anastomoses 
between bovine twins. Science (1945) 102(2651):400–1. doi:10.1126/
science.102.2651.400 
2. Burnet F, Fenner F. The Production of Antibodies. Monograph of the Walter 
and Eliza Hall Institute. Melbourne (1949). p. viii + 142.
3. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign 
cells. Nature (1953) 172(4379):603–6. doi:10.1038/172603a0 
4. Guenther DA, Madsen JC. Advances in strategies for inducing central tol-
erance in organ allograft recipients. Pediatr Transplant (2005) 9(3):277–81. 
doi:10.1111/j.1399-3046.2005.00308.x 
5. West LJ. B-cell tolerance following ABO-incompatible infant heart 
transplantation. Transplantation (2006) 81(3):301–7. doi:10.1097/01.
tp.0000203829.78700.f3 
6. Touraine JL, Sanhadji K. Transplantation tolerance induced in humans 
at the fetal or the neonatal stage. J Transplant (2011) 2011:760319. 
doi:10.1155/2011/760319 
dendritic cells, or MHC allopeptides, could induce donor-specific 
tolerance to organ allografts (155–158).
Although intrathymic injection of donor antigen has been 
demonstrated to be very effective in rodents, successful stud-
ies in large animals have not been reported. But interestingly, 
intrathymic injection has been applied to humans in a clinical 
trial of pediatric heart transplantation reported by Remuzzi et al. 
(159). Thirty-seven children (median age of 7.4  years) entered 
the study. Fourteen patients received intrathymic inoculation of 
8 × 107 cells/kg of unmodified donor BMCs prior to sternal clo-
sure; 23 patients for whom marrow could not be harvested acted 
as controls. All patients received standard tacrolimus-based IS 
without induction therapy. Freedom from acute cellular rejection 
and the number of rejection episodes was not different between 
the study group and control group in the first 6  months after 
transplant. However, there was a greater freedom from late acute 
cellular rejection (beyond 1  year) in the study group. Among 
the 13 survivors in the study group, only 2 episodes of late acute 
cellular rejection were reported. By contrast, 20 episodes were 
detected in the 22 surviving controls. However, serial MLR using 
irradiated donor and third-party splenocytes showed no evidence 
of increased hyporesponsiveness in the intrathymic injection 
group. This clinical trial indicated that intrathymic injection with 
donor bone marrow is feasible and safe in the setting of pediatric 
heart transplantation. However, the outcome was not promising 
enough to allow this approach to be widely performed with other 
organ transplantations, such as renal transplant. Indeed, if we 
consider that except for heart transplant, organ transplantations 
do not share the same surgical access with thymic injection 
and intrathymic injection, these interventions would thus be 
either too invasive in the case of open-chest surgery or almost 
impossible to achieve right orientation to thymus. Several other 
disadvantages may include the fact that (i) intrathymic injection 
cannot be performed in adult patients in whom the thymus has 
undergone involution and (ii) intrathymic injection can neither 
eliminate the donor-reactive T-lymphocytes that preexisted nor 
prevent their expansion into the peripheral blood.
CONCLUSiON
The first pediatric SOT was performed in Paris in 1953 by Michon 
and Hamburger et al., but this mother-to-son living kidney trans-
plant failed because of the lack of immunosuppressive medication 
(160). Since then, enormous progress has been accomplished in 
the domain of pediatric transplantation. Based on the infusion 
of donor hematopoietic cells and mixed chimerism creation, 
several tolerance induction approaches have been successfully 
implemented in adult renal transplantation, although accompa-
nied with certain complications, such as engraftment syndrome. 
However, so far, no tolerance induction protocol has been tested 
for pediatric SOT.
Young pediatric transplant recipients have a great demand for 
tolerance induction regimens. They required longer survival time 
of allograft and may thus suffer more undesirable effects and risks 
related to long-term IS. Furthermore, they are more susceptible 
to chronic rejection, allograft amputation, and re-transplantation. 
However, newborn infants possess more advantage for central tol-
erance induction, because of their premature immune system and 
their highly developed thymus. Approaches of tolerance induction 
via hematopoietic cell therapies have achieved promising results 
in renal transplants in adults, and they should be evaluated in 
young pediatric recipients, if less toxic but effective conditioning 
regimens could be defined for these vulnerable children.
However, we must realize that the mechanisms underly-
ing immune tolerance may vary between different solid organ 
allotransplants or composite tissue allotransplants. We may not 
be able to directly extend the experiences gained from tolerance 
induction in renal allografts to other types of allografts but have to 
investigate more specific tolerance induction protocols and IS with-
drawal programs. Besides, for such applications in human infants, 
we must be able to recognize the tolerance-vulnerable patients and 
at least at the beginning, try to find better HLA-matched donors. 
In this regard, some criteria and potential biomarkers have been 
identified (131, 161). However, the identification of suitable 
biomarkers for the minimization or weaning of IS remains a chal-
lenge, which should be one of the main focuses of future studies.
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